Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares conducted on July 23, 2025, and filed on July 24, 2025. The Company, a foreign private issuer, executed these purchases through its corporate stockbroker, Merrill Lynch International, pursuant to a non-discretionary agreement entered into on June 4, 2025.
Key Financial Metrics and Transaction Details
The filing details a specific share buyback transaction rather than full-period financial results. Key metrics for the transaction on July 23, 2025, include:
- Shares Purchased: 491,680 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,364.50p; highest price paid was 1,374.50p.
- Volume-Weighted Average Price (VWAP): 1,369.42p.
- Trading Venue: All purchases occurred on the London Stock Exchange (XLON).
- Treasury Share Holdings: Following this purchase, the Company holds 234,320,109 ordinary shares in treasury.
- Shares in Issue: 4,081,064,171 ordinary shares (excluding Treasury shares).
- Voting Rights: Treasury shares represent 5.74% of total voting rights.
Since the commencement of the buyback programme on June 4, 2025, the Company has purchased a total of 16,185,726 ordinary shares.
Material Changes
The filing does not report material changes to revenue, profit, or operational performance. The primary change reported is the reduction of shares in issue and the increase in treasury shares resulting from the buyback activity. The total number of voting rights remains 4,081,064,171, which serves as the denominator for shareholder notification calculations under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Guidance, Outlook, and Risks
The filing contains no new financial guidance or management commentary regarding future operational outlook. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks described in the Company's Annual Report on Form 20-F for 2024 and Q1 Results for 2025. No unusual items or contingencies were disclosed in this specific transaction report.
Investor Verification Checklist
- Verify the total number of shares purchased under the buyback programme since June 4, 2025 (16,185,726 shares).
- Confirm the current percentage of voting rights held in treasury (5.74%) against regulatory thresholds.
- Review the non-discretionary agreement terms with Merrill Lynch International to understand the remaining capacity of the buyback programme.
- Check the Company's Form 20-F for 2024 and Q1 2025 results for the full context of risk factors mentioned in the cautionary statement.